Marshall Wace LLP Acquires 72,114 Shares of Cabot Co. (NYSE:CBT)

Marshall Wace LLP lifted its holdings in shares of Cabot Co. (NYSE:CBT - Free Report) by 3,242.5% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,338 shares of the specialty chemicals company's stock after acquiring an additional 72,114 shares during the quarter. Marshall Wace LLP owned 0.14% of Cabot worth $6,788,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the business. R Squared Ltd bought a new stake in shares of Cabot in the 4th quarter worth approximately $26,000. EverSource Wealth Advisors LLC raised its stake in shares of Cabot by 37.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company's stock valued at $74,000 after buying an additional 219 shares during the period. GAMMA Investing LLC raised its stake in shares of Cabot by 10.7% in the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company's stock valued at $123,000 after buying an additional 130 shares during the period. Manchester Capital Management LLC lifted its position in shares of Cabot by 1,685.1% during the 4th quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company's stock valued at $153,000 after buying an additional 1,584 shares during the last quarter. Finally, KBC Group NV grew its stake in shares of Cabot by 43.1% during the 4th quarter. KBC Group NV now owns 2,046 shares of the specialty chemicals company's stock worth $187,000 after acquiring an additional 616 shares during the period. 93.18% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

CBT has been the subject of several recent research reports. JPMorgan Chase & Co. reduced their price target on Cabot from $105.00 to $85.00 and set an "underweight" rating for the company in a research report on Friday, February 21st. Mizuho lowered their price objective on shares of Cabot from $122.00 to $110.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. StockNews.com upgraded shares of Cabot from a "hold" rating to a "buy" rating in a research report on Thursday, April 17th. Finally, UBS Group lowered their price target on Cabot from $93.00 to $83.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th.

Cabot Price Performance

Shares of CBT stock traded up $0.07 during trading hours on Tuesday, hitting $79.04. 44,567 shares of the company's stock were exchanged, compared to its average volume of 389,245. Cabot Co. has a 12-month low of $73.63 and a 12-month high of $117.46. The company has a market capitalization of $4.29 billion, a PE ratio of 10.50, a PEG ratio of 0.74 and a beta of 1.04. The business's 50 day simple moving average is $81.74 and its 200-day simple moving average is $93.34. The company has a current ratio of 2.00, a quick ratio of 1.29 and a debt-to-equity ratio of 0.72.

Cabot (NYSE:CBT - Get Free Report) last posted its quarterly earnings results on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.74 by $0.02. Cabot had a net margin of 10.60% and a return on equity of 26.79%. On average, equities research analysts anticipate that Cabot Co. will post 7.57 earnings per share for the current year.

Cabot Company Profile

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.